Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | RAB9A | P51151 | 6/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.35 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL573354 | 0.84 | ALDH1A1 (0.63) | ALDH1A1KMT2AKDM4ERAB9AMIF | |
| SCHEMBL272269 | 0.84 | ALDH1A1 (0.63) | ALDH1A1KMT2AMAPTKDM4ERAB9A | |
| SCHEMBL12779155 | 0.83 | ALDH1A1 (0.61) | ALDH1A1KMT2AKDM4ERAB9ARECQL | |
| SCHEMBL182243 | 0.83 | ALDH1A1 (0.61) | ALDH1A1KMT2AKDM4ERAB9ARECQL | |
| SCHEMBL1406859 | 0.80 | KMT2A (0.58) | ALDH1A1KMT2AMAPTKDM4ERAB9A | |
| SCHEMBL2672312 | 0.80 | KMT2A (0.58) | ALDH1A1KMT2AMAPTKDM4ERAB9A | |
| SCHEMBL20583542 | 0.79 | ALDH1A1 (0.57) | ALDH1A1KMT2AMAPTKDM4ERAB9A | |
| SCHEMBL5230106 | 0.79 | ALDH1A1 (0.69) | ALDH1A1KMT2AMAPTKDM4ERAB9A | |
| SCHEMBL4034600 | 0.79 | KDM4E (0.59) | ALDH1A1KMT2AMAPTKDM4ERAB9A | |
| Hydrochloric Acid SCHEMBL1781552 | 0.79 | KMT2A (0.57) | ALDH1A1KMT2AMAPTKDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113166161-B | Compounds having PDE9A inhibiting activity and pharmaceutical uses thereof | 韩国化学研究院 | 2023-10-27 | — | — | CN | disclosed |
| CN-113166159-B | Compounds having PDE9A inhibiting activity and pharmaceutical uses thereof | 韩国化学研究院 | 2023-10-24 | — | — | CN | disclosed |
| EP-3672958-B1 | ANNULATED GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2023-08-02 | — | — | EP | disclosed |
| US-20220024932-A1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-01-27 | — | — | US | disclosed |
| US-20220017528-A1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-01-20 | — | — | US | disclosed |
| CN-113166159-A | Compound with PDE9A inhibitory activity and pharmaceutical use thereof | 韩国化学研究院 | 2021-07-23 | — | — | CN | disclosed |
| CN-113166161-A | Compound with PDE9A inhibitory activity and pharmaceutical use thereof | 韩国化学研究院 | 2021-07-23 | — | — | CN | disclosed |
| US-20200289516-A1 | ANNULATED GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2020-09-17 | — | — | US | disclosed |
| WO-2020116972-A1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | 한국화학연구원 | 2020-06-11 | — | — | WO | disclosed |
| WO-2020116972-A1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | 한국화학연구원 | 2020-06-11 | — | — | WO | disclosed |
| WO-2020116971-A1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | 한국화학연구원 | 2020-06-11 | — | — | WO | disclosed |
| US-20100094000-A1 | PYRAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100094000-A1 | PYRAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289516-A1 | ANNULATED GLYCOSIDASE INHIBITORS | GAA, GBA3, ENGASE | ALDH1A1 1208/4885KMT2A 1472/4885MAPT 26/4885 |
| US-20220024932-A1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | PDE9A, PDE5A, PDE3A | ALDH1A1 517/4885KMT2A 1360/4885MAPT 3479/4885 |
| US-20220017528-A1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | PDE9A, PDE5A, PDE3A | ALDH1A1 517/4885KMT2A 1360/4885MAPT 3479/4885 |
| US-20100094000-A1 | PYRAZOLE COMPOUNDS | NR3C2, MC2R, NR3C1 | ALDH1A1 1704/4885KMT2A 2289/4885MAPT 2903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.